MedTrace Logo

Japanese Pediatric H5N1 Vaccine Study

NCT01911754 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2015-10-09

No results posted yet for this study

Summary

The purpose of this study is to obtain immunogenicity and safety data of an H5N1 pandemic influenza vaccine in a Japanese pediatric population aged 6 months to 17 years

Conditions

Interventions

BIOLOGICAL

H5N1 (Pre-)Pandemic Influenza Vaccine (Whole Virion, Vero Cell-Derived, Inactivated)

Sponsors & Collaborators

  • Baxter Innovations GmbH

    collaborator INDUSTRY

  • Alachua Government Services, Inc.

    lead INDUSTRY

Principal Investigators

  • Nirjhar Chatterjee, MD · Baxter Innovations GmbH

Study Design

Allocation
NA
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
6 Months
Max Age
17 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-08-31
Primary Completion
2013-11-30
Completion
2014-04-30

Countries

  • Japan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01911754 on ClinicalTrials.gov